Pharvaris' deucrictibant scores well in Phase II HAE study

Shares of Switzerland-based clinical-stage drug developer Pharvaris (Nasdaq: PHVS) rose by as much as 42% Wednesday morning, as it announced positive top-line data from the CHAPTER-1 Phase II clinical study meeting its primary endpoint, with deucrictibant.

The trial demonstrated statistically-significant and clinically-meaningful results of deucrictibant as an oral preventative treatment for people living with hereditary angioedema (HAE). Pharvaris plans to present data from the study at future medical meetings.

CHAPTER-1 ( NCT05047185) is a double-blind, placebo-controlled Phase II study evaluating the efficacy as well as the safety and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE-1/2. In the study, 34 participants were enrolled globally and randomized to receive one of two doses of deucrictibant (20mg/day or 40mg/day) or placebo for 12 weeks of treatment.